Literature DB >> 9310492

Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy.

G Ferrari1, C Berend, J Ottinger, R Dodge, J Bartlett, J Toso, D Moody, J Tartaglia, W I Cox, E Paoletti, K J Weinhold.   

Abstract

In the attempt to develop immunotherapeutic strategies for acquired immunodeficiency syndrome capable of activating effector cells in an antigen-specific manner while maintaining the broadest possible T-cell repertoire, we evaluated two canarypox (ALVAC)-based vectors for their capacity to induce ex vivo activation/expansion of human immunodeficiency virus (HIV)-specific CD8+ cytotoxic lymphocyte precursors (CTLp) obtained from HIV-1-infected donors. These two vectors, vCP205 encoding HIV-1 gp120 + TM (28 amino acid transmembrane anchor sequence) in addition to Gag/protease and vCP300 encoding gp120 + Gag/protease as well as Nef and Pol CTL determinants, are pancytotropic but replication incompetent in mammalian cells. Bulk peripheral blood mononuclear cells (PBMCs) or enriched CD8+ T cells were stimulated for 10 days with autologous ALVAC-infected PBMCs in the presence of different cytokine combinations (interleukin-2 [IL-2], IL-4, IL-7, and IL-12). Activation by ALVAC constructs was highly antigen-specific, because vCP205 elicited only Env and Gag CTL, whereas vCP300 elicited broader reactivities against Env, Gag, Pol, and Nef determinants. The ALVAC activation of CTLp was IL-2 dependent and enhanced by the addition of IL-7, whereas IL-4 and IL-12 failed to augment cytotoxic reactivities elicited by these constructs. The expansion of enriched CD8+ T cells after activation with vCP300 was higher in patients with CD4 counts greater than 400 cells/microL. Two rounds of in vitro stimulation (IVS) with vCP300 resulted in nearly an eightfold expansion of CD8+ lymphocytes over a 25-day period. After the second IVS, an average 3.2-fold increase among the different antigen-specific CTL frequencies was achieved. These studies clearly show that HIV-recombinant ALVAC vectors represent powerful polyvalent antigenic stimuli for activation and expansion of the CD8 lymphocyte response that occurs as a result of HIV infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9310492

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.

Authors:  S Gnjatic; Y Nagata; E Jager; E Stockert; S Shankara; B L Roberts; G P Mazzara; S Y Lee; P R Dunbar; B Dupont; V Cerundolo; G Ritter; Y T Chen; A Knuth; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

2.  A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon.

Authors:  P A Goepfert; A Bansal; B H Edwards; G D Ritter; I Tellez; S A McPherson; S Sabbaj; M J Mulligan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Induction of human immunodeficiency virus (HIV)-specific CD8 T-cell responses by Listeria monocytogenes and a hyperattenuated Listeria strain engineered to express HIV antigens.

Authors:  R S Friedman; F R Frankel; Z Xu; J Lieberman
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Recombinant nipah virus vaccines protect pigs against challenge.

Authors:  Hana M Weingartl; Yohannes Berhane; Jeff L Caswell; Sheena Loosmore; Jean-Christophe Audonnet; James A Roth; Markus Czub
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

5.  Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression.

Authors:  Y Huang; W P Kong ; G J Nabel
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

6.  Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes.

Authors:  T Woodberry; J Gardner; L Mateo; D Eisen; J Medveczky; I A Ramshaw; S A Thomson; R A Ffrench; S L Elliott; H Firat; F A Lemonnier; A Suhrbier
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

7.  Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses.

Authors:  B Poon; J F Hsu; V Gudeman; I S Y Chen; K Grovit-Ferbas
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

8.  Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses.

Authors:  Xuemin Chen; Michael T Rock; Jason Hammonds; James Tartaglia; Ayumi Shintani; Jeff Currier; Bonnie Slike; James E Crowe; Mary Marovich; Paul Spearman
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

9.  Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals.

Authors:  J Engelmayer; M Larsson; A Lee; M Lee; W I Cox; R M Steinman; N Bhardwaj
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

10.  Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines.

Authors:  Jan zur Megede; Gillis R Otten; Barbara Doe; Hong Liu; Louisa Leung; Jeffrey B Ulmer; John J Donnelly; Susan W Barnett
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.